Recent advances in treatment of heart failure [version 1; referees: 2 approved]

Abstract

With the total cases and economic burden of heart failure continuing to rise, there is an overwhelming need for novel therapies. Several drugs for heart failure have succeeded in preclinical and early-phase clinical trials, but most of them failed to show the real benefit in pivotal clinical trials. Meanwhile, the US Food and Drug Administration recently approved two promising new drugs to treat heart failure: ivabradine and sacubitril/valsartan. Furthermore, some of the newer agents in testing offer the potential for significant progress in addition to these drugs. Patiromer and zirconium cyclosilicate are attractive agents that are expected to prevent hyperkalemia during renin-angiotensin-aldosterone system inhibition, and serelaxin and urodilatin are promising drugs in the treatment of acute heart failure. Future clinical trials with more appropriate study designs, optimal clinical endpoints, and proper patient selection are mandatory to assess the true efficacy of these attractive compounds in clinical practice.

Keywords

• Cardiovascular Pharmacology
• Cardiovascular Physiology/Circulation
• Coronary Artery Disease
• Geriatric Cardiology
• Heart Failure
• Mineral Metabolism & the Kidney
• Pathophysiology of Chronic Kidney Disease (CKD)
• Renal Pharmacology